<p><strong>Metastatic Breast Cancer</strong>: After failure of combination chemotherapy for metastatic breast cancer or relapse within 6 months of&nbsp;adjuvant&nbsp;chemotherapy, the recommended regimen for Nab-Paclitaxel is 260 mg/m&sup2; administered intravenously over 30 minutes every 3 weeks.<br />
<br />
<strong>Non-Small Cell Lung Cancer</strong>: The recommended dose of Nab-Paclitaxel is 100 mg/m&sup2; administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Administer carboplatin on Day 1 of each 21 day cycle immediately after Nab-Paclitaxel.<br />
<br />
<strong>Adenocarcinoma Of The Pancreas</strong>: The recommended dose of Nab-Paclitaxel is 125 mg/m&sup2; administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle. Administer gemcitabine immediately after Nab-Paclitaxel on Days 1, 8 and 15 of each 28-day cycle.<br />
<br />
<strong>Dosage In Patients With Hepatic Impairment</strong>: For patients with mild hepatic impairment (total bilirubin greater than ULN and less than or equal to 1.5 x ULN and&nbsp;aspartate aminotransferase&nbsp;[AST] less than or equal to 10 x ULN), no dose adjustments are required, regardless of indication.<br />
<br />
Do not administer Nab-Paclitaxel to patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment. Do not administer Nab-Paclitaxel to patients with total bilirubin greater than 5 x ULN or AST greater than 10 x ULN regardless of indication as these patients have not been studied.</p>